Relationship Between LTA4H Promotor Polymorphism and Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome and Its Prevention With Prednisone

Cari Stek; Muki Shey; Khuthala Mnika; Charlotte Schutz; Friedrich Thienemann; Robert J Wilkinson; Lutgarde Lynen; Graeme Meintjes

doi:10.1093/ofid/ofad379

Relationship Between LTA4H Promotor Polymorphism and Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome and Its Prevention With Prednisone

Open Forum Infect Dis. 2023 Jul 17;10(7):ofad379. doi: 10.1093/ofid/ofad379. eCollection 2023 Jul.

Authors

Cari Stek^{1

2

3}, Muki Shey^{1

3}, Khuthala Mnika⁴, Charlotte Schutz^{1

3}, Friedrich Thienemann^{1

3}, Robert J Wilkinson^{1

3

5

6}, Lutgarde Lynen², Graeme Meintjes^{1

3}

Affiliations

¹ Wellcome Center for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
² Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
³ Department of Medicine, University of Cape Town, Cape Town, South Africa.
⁴ Division of Human Genetics, Department of Pathology, University of Cape Town, Cape Town, South Africa.
⁵ Francis Crick Institute, London, United Kingdom.
⁶ Department of Infectious Diseases, Imperial College London, London, United Kingdom.

Abstract

The development of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) and its prevention using prednisone may potentially be mediated by the LTA4H genotype. We assessed this hypothesis in a clinical trial evaluating prednisone to prevent TB-IRIS. We did not find an association between LTA4H genotype and TB-IRIS incidence or prednisone efficacy.

Keywords: IRIS; LTA4H genotype; corticosteroids; immune reconstitution inflammatory syndrome; tuberculosis.

Grants and funding

211360/Z/18/Z/WT_/Wellcome Trust/United Kingdom